Last €30.17 EUR
Change Today +0.12 / 0.40%
Volume 190.4K
GNFT On Other Exchanges
EN Paris
As of 11:35 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

genfit (GNFT) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/18/14 - €36.64
52 Week Low
09/4/13 - €5.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENFIT (GNFT)

Related News

No related news articles were found.

genfit (GNFT) Related Businessweek News

No Related Businessweek News Found

genfit (GNFT) Details

Genfit SA, a biopharmaceutical company, focuses on the development of therapeutic and diagnostic solutions for prevention and treatment of diabetes and related disorders worldwide. The company conducts research and development programs in the therapeutic areas of cardiometabolic disorders, including hepatic and cardiovascular complications, such as Non-Alcoholic Steato-Hepatitis (NASH). Its lead drug candidate includes GFT505, which is in Phase II clinical trials for the treatment of NASH. The company is also developing TGFTX1 program that targets the RORt receptor, which is a pathological player in the etiology of auto-immune diseases, including psoriasis and rheumatoid arthritis; and TGFTX3 program that develops proprietary compounds, which activate the nuclear receptor Rev-Erb, a key player in the regulation of circadian rhythm. In addition, it is developing IT-Diab program for diagnostic and therapeutic solutions for prediabetes and the early stages of Type 2 diabetes; and biomarker programs for the early detection of Type 2 diabetes and atherosclerosis. Further, the company provides health research services for biotechs; and pharmaceutical, nutraceutical, and cosmetic companies. Genfit SA has collaboration with Sanofi-Aventis and Solvay. The company was founded in 1999 and is headquartered in Loos, France.

78 Employees
Last Reported Date: 03/12/14
Founded in 1999

genfit (GNFT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

genfit (GNFT) Key Developments

Genfit SA(ENXTPA:GNFT) added to CAC All-Tradable Index

Genfit SA will be added to the CAC All-Tradable Index.

Genfit SA(ENXTPA:GNFT) added to SBF 120 Index

Genfit SA will be added to the SBF 120 Index.

Genfit SA, Annual General Meeting, Jun 20, 2014

Genfit SA, Annual General Meeting, Jun 20, 2014., at 10:30 Central European Standard Time. Location: Pharmaceutical & Biological Sciences of Lille premises.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNFT:FP €30.17 EUR +0.12

GNFT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GNFT.
View Industry Companies

Industry Analysis


Industry Average

Valuation GNFT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 101.9x
Price/Book 42.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 112.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENFIT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at